author-photo

Moshe Yair Levy

Baylor University

10

Papers

77

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

DASFREE: Treatment-Free Remission (TFR) After Discontinuation of Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Phase 2b Results of the STORM Study: Oral Selinexor plus Low Dose Dexamethasone (Sd) in Patients with Penta-Refractory Myeloma (penta-MM)

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (5)
Results of the Pivotal STORM Study (Part 2) in Penta-Refractory Multiple Myeloma (MM): Deep and Durable Responses with Oral Selinexor Plus Low Dose Dexamethasone in Patients with Penta-Refractory MM

2018 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Updated 18-Month Results from Dasfree: A Study Evaluating Dasatinib Discontinuation in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Deep Molecular Response (DMR)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE)

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Phase I trial of alpha-particle immunotherapy with 225Ac-lintuzumab and low-dose cytarabine in patients age 60 or older with untreated acute myeloid leukemia.

2017 The Journal of Nuclear Medicine
Show All
- Source
- Cite
- Save
Citations (6)
Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)